Application of genetic testing for the diagnosis of von Willebrand disease
J Thromb Haemost. 2024 May 16:S1538-7836(24)00288-5. doi: 10.1016/j.jtha.2024.05.006. Online ahead of print.ABSTRACTvon Willebrand disease (VWD) is the most frequent inherited bleeding disorder with an estimated symptomatic prevalence of 1 per 1,000 in the general population. VWD is characterized by defects in the quantity, quality, or multimeric structure of von Willebrand factor (VWF), a glycoprotein being hemostatically essential in circulation. It is classified into three principal types; Low VWF/type 1 with partial quantitative deficiency of VWF, type 3 with virtual absence of VWF, and type 2 with functional abnormali...
Source: Thrombosis and Haemostasis - May 18, 2024 Category: Hematology Authors: Omid Seidizadeh Luciano Baronciani David Lillicrap Flora Peyvandi Source Type: research
Acute Q fever revealed by an anti-phospholipid syndrome: A case report
CONCLUSION: During acute C. burnetii infections, anti-phospholipid antibodies are highly prevalent but thrombotic complications are rare. The 2023 ACR/EULAR APS criteria restricts the diagnosis of APS, as in our case of acute severe infection. In front of an atypical pneumonia and/or thrombotic events, screening of C. burnetii and anti-phospholipid antibodies could be useful. Given its low level of evidence, prolongated treatment by doxycycline, hydroxychloroquine ± anticoagulant for C. burnetii's associated anti-phospholipid syndrome is discussed, but succeeded in our case.PMID:38762438 | DOI:10.1016/j.revmed.2024.05.006...
Source: Revue de Medecine Interne - May 18, 2024 Category: Internal Medicine Authors: K Balasoupramanien J-B Roseau N Cazes C Surcouf E Le Dault Source Type: research
Coagulating blood into adhesive gel by hybrid powder based on oppositely charged polysaccharide/tannic acid-modified mesoporous bioactive glass
This study introduces a hemostatic powder composed of tannic modified mesoporous bioactive glass (TMBG), cationic quaternized chitosan (QCS), and anionic hyaluronic acid modified with catechol group (HADA). The resulting TMBG/QCS/HADA based hemostatic powder (TMQH) rapidly absorbs plasma, concentrating blood coagulation factors. Simultaneously, the water-soluble QCS and HADA interact to form a 3D network structure, which can be strengthened by crosslinking with TMBG. This network effectively captures clustered blood coagulation factors, leading to a strong and adhesive thrombus that resists disruption from blood flow. TMQH...
Source: International Journal of Biological Macromolecules - May 18, 2024 Category: Biochemistry Authors: Yan Fang Yukai Lin Linyu Wang Xinwei Zheng Qinhui Chen Yunxiang Weng Haiqing Liu Source Type: research
Microplastics in human blood: Polymer types, concentrations and characterisation using μFTIR
This study adds to the growing evidence that MPs are taken up into the human body and are transported via the bloodstream. The shape and sizes of the particles raise important questions with respect to their presence and associated hazards in terms of potential detrimental impacts such as vascular inflammation, build up within major organs, and changes to either immune cell response, or haemostasis and thrombosis.PMID:38761430 | DOI:10.1016/j.envint.2024.108751 (Source: Environment International)
Source: Environment International - May 18, 2024 Category: Environmental Health Authors: Sophie V L Leonard Catriona R Liddle Charlotte A Atherall Emma Chapman Matthew Watkins Simon D J Calaminus Jeanette M Rotchell Source Type: research
Acute Q fever revealed by an anti-phospholipid syndrome: A case report
CONCLUSION: During acute C. burnetii infections, anti-phospholipid antibodies are highly prevalent but thrombotic complications are rare. The 2023 ACR/EULAR APS criteria restricts the diagnosis of APS, as in our case of acute severe infection. In front of an atypical pneumonia and/or thrombotic events, screening of C. burnetii and anti-phospholipid antibodies could be useful. Given its low level of evidence, prolongated treatment by doxycycline, hydroxychloroquine ± anticoagulant for C. burnetii's associated anti-phospholipid syndrome is discussed, but succeeded in our case.PMID:38762438 | DOI:10.1016/j.revmed.2024.05.006...
Source: Revue de Medecine Interne - May 18, 2024 Category: Internal Medicine Authors: K Balasoupramanien J-B Roseau N Cazes C Surcouf E Le Dault Source Type: research
Application of genetic testing for the diagnosis of von Willebrand disease
J Thromb Haemost. 2024 May 16:S1538-7836(24)00288-5. doi: 10.1016/j.jtha.2024.05.006. Online ahead of print.ABSTRACTvon Willebrand disease (VWD) is the most frequent inherited bleeding disorder with an estimated symptomatic prevalence of 1 per 1,000 in the general population. VWD is characterized by defects in the quantity, quality, or multimeric structure of von Willebrand factor (VWF), a glycoprotein being hemostatically essential in circulation. It is classified into three principal types; Low VWF/type 1 with partial quantitative deficiency of VWF, type 3 with virtual absence of VWF, and type 2 with functional abnormali...
Source: Thrombosis and Haemostasis - May 18, 2024 Category: Hematology Authors: Omid Seidizadeh Luciano Baronciani David Lillicrap Flora Peyvandi Source Type: research
Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism
CONCLUSIONS: Recurrent DVT and PE were frequent but had low CFRs (0.4% and 4.6%, respectively) after discontinuing anticoagulation. Contrary, major bleeding was rare, but had high CFR (24%). A few clinical factors may predict these outcomes.PMID:38762019 | DOI:10.1016/j.jtha.2024.05.007 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - May 18, 2024 Category: Hematology Authors: Cristina Gabara Jesus Aibar Yuji Nishimoto Yugo Yamashita Paolo Prandoni Geoffrey D Barnes Behnood Bikdeli David Jim énez Pablo Demelo-Rodr íguez Ma Luisa Peris Son Truong Nguyen Manuel Monreal RIETE Investigators Source Type: research
Obituary Prof. Margareta "Meta" Blomb äck (1925-2024)
J Thromb Haemost. 2024 May 16:S1538-7836(24)00286-1. doi: 10.1016/j.jtha.2024.04.024. Online ahead of print.NO ABSTRACTPMID:38762020 | DOI:10.1016/j.jtha.2024.04.024 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - May 18, 2024 Category: Hematology Authors: Jovan P Antovic Maria S Magnusson Hans Johnsson Source Type: research
The use of 1e12, a monoclonal anti-platelet factor 4 antibody to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia
CONCLUSIONS: A simple competitive anti-PF4 EIA with 1E12 could help confirm VITT diagnosis and distinguish it from HIT in patients when both diagnoses are possible.PMID:38762021 | DOI:10.1016/j.jtha.2024.05.005 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - May 18, 2024 Category: Hematology Authors: Caroline Vayne J érôme Rollin Rumi Clare Mercy Daka Merveille Atsouawe Eve-Anne Gu éry Philippe Cauchie Charlotte Cordonnier Pauline Cuisenier Emmanuel De Maistre Magali Donnard Nicolas Drillaud Doroth ée Faille Hubert Galinat Isabelle Gouin-Thibault Source Type: research
Editorial Board
(Source: Thrombosis Research)
Source: Thrombosis Research - May 18, 2024 Category: Hematology Source Type: research
Statins use and recurrent venous thromboembolism in the direct oral anticoagulant era: insight from the COMMAND VTE Registry-2
AbstractStatins were reported to have a potential effect of primary prevention of venous thromboembolism (VTE), although that of secondary prevention remains uncertain. To investigate the association between statins use and recurrent VTE in the current era. The COMMAND VTE Registry-2 is a multicenter registry enrolling 5,197 consecutive VTE patients among 31 centers in Japan between January 2015 and August 2020. We divided the entire cohort into 2 groups according to statins use at the time of discharge; the statins (N = 865) and no statins groups (N = 4332). The statins group was older (72.9 vs. 66.7 years,P <...
Source: Journal of Thrombosis and Thrombolysis - May 18, 2024 Category: Hematology Source Type: research
Optimal hemodynamic parameters for risk stratification in acute pulmonary embolism patients
AbstractHemodynamic assessment of patients with pulmonary embolism (PE) remains a fundamental component of early risk stratification that in turn, influences subsequent monitoring and therapeutic strategies. The current body of literature and international evidence-based clinical practice guidelines focus mainly on the use of systolic blood pressure (SBP). The accuracy of this single hemodynamic parameter, however, and its optimal values for the identification of hemodynamic instability have been recently questioned by clinicians. For example, abnormal SBP or shock index may be a late indicator of adverse outcomes, signali...
Source: Journal of Thrombosis and Thrombolysis - May 18, 2024 Category: Hematology Source Type: research
Factor XI as a new target for prevention of thromboembolism in cardiovascular disease: a meta-analysis of randomized controlled trials
AbstractAnticoagulant therapy is a mainstay in the management of patients with cardiovascular disease. The use of conventional anticoagulants carries potential side effects, mainly bleeding. Drugs targeting Factor XI (FXI) have been investigated in randomized controlled trials as a new option with more favorable outcomes. A comprehensive literature search was conducted to identify relevant studies comparing FXI inhibitors to placebo or standard therapy. The primary outcomes were incidence of all bleeding events, major bleeding, and thromboembolism. Secondary outcomes included incidence of all adverse events (AE), serious A...
Source: Journal of Thrombosis and Thrombolysis - May 18, 2024 Category: Hematology Source Type: research
Predictors of bleeding and thrombotic events among patients admitted to the hospital with COVID-19 and elevated D-dimer: insights from the ACTION randomized clinical trial
AbstractTherapeutic anticoagulation showed inconsistent results in hospitalized patients with COVID-19 and selection of the best patients to use this strategy still a challenge balancing the risk of thrombotic and hemorrhagic outcomes. The present post-hoc analysis of the ACTION trial evaluated the variables independently associated with both bleeding events (major bleeding or clinically relevant non-major bleeding) and the composite outcomes thrombotic events (venous thromboembolism, myocardial infarction, stroke, systemic embolism, or major adverse limb events). Variables were assessed one by one with independent logisti...
Source: Journal of Thrombosis and Thrombolysis - May 18, 2024 Category: Hematology Source Type: research
Optimizing resource allocation: Cost-effectiveness of specified D-dimer cut-offs in cancer patients with suspected venous thromboembolism
AbstractAn accurate diagnosis of venous thromboembolism (VTE) is crucial, given the potential for high mortality in undetected cases. Strategic D-dimer testing may aid in identifying low-risk patients, preventing overdiagnosis and reducing imaging costs. We conducted a retrospective, comparative analysis to assess the potential cost savings that could be achieved by adopting different approaches to determine the most effective D-dimer cut-off value in cancer patients with suspected VTE, compared to the commonly used rule-out cut-off level of 0.5 mg/L. The study included 526 patients (median age 65, IQR 55–75) with a co...
Source: Journal of Thrombosis and Thrombolysis - May 18, 2024 Category: Hematology Source Type: research
